Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06528028

Relationship Between Different Administration Regimens of Ceftazidime/Avibactam and Clinical Outcomes

Relationship Between Different Administration Regimens of Ceftazidime/Avibactam and Clinical Outcomes in Patients With Severe Infection: a Multicenter, Prospective, Randomized Controlled Study

Status
Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
140 (estimated)
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Ceftazidime/avibactam (CAZ/AVI) is a new β-lactam drug, which has good antibacterial effect against carbapenem resistant enterobacter. However, previous studies found that CAZ/AVI had a low PK/PD compliance rate after the recommended dose of the drug instructions.Therefore, this study was intended to explore the clinical efficacy of different administration schedules of CAZ/AVI for patients with severe infection, and further analyze the correlation between CAZ/AVI PK/PD parameters and clinical efficacy and adverse reactions.

Detailed description

1. Main purpose The main objective of this study was to verify that the clinical efficacy of treatment group (load dose of 2.5g, then continuous infusion of 2.5gQ8h, the dose can be adjusted according to renal function) with severe infection was superior to that of the control group (standard dose and administration regimen of ceftazidime/avibactam, i.e. 2.5gQ8h, 2h infusion).Dose can be adjusted according to renal function). 2. Secondary purpose (1) To investigate the relationship between different administration regimens and bacterial clearance and 28-d mortality (2) To explore the correlation between different dosing regimens and PK/PD compliance rate (3) To explore the correlation between different administration regimens and adverse drug reactions

Conditions

Interventions

TypeNameDescription
DRUGCAZ/AVIcontinuous infusion is used
DRUGCAZ/AVI2h-infusion is used

Timeline

Start date
2024-07-01
Primary completion
2025-06-30
Completion
2025-07-30
First posted
2024-07-30
Last updated
2024-07-30

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06528028. Inclusion in this directory is not an endorsement.